Insmed's CEO keeps a newspaper story from 2014 in his office. The headline: “Insmed joins the biotech trash heap.” Now, he hopes the company can be a $100 billion biotech.

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is one of the best biotech stocks to invest in now. On June 3, Amylyx Pharmaceuticals announced that the US FDA granted Fast Track designation to AMX0114.

A South Korean Biotech Firms Gets $183.3M Funding to Build Bitcoin Treasury The company is also preparing to list on public markets in the U.S. via a special purpose acquisition company, SilverBox ...

A UK biotech firm spent years gathering genetic data that has uncovered 1 million previously unknown microbial species and billions of newly identified genes – but even this trove of data may ...

The Massachusetts biotech industry produces an astonishing 15 percent of the entire US drug development pipeline and employs nearly 117,000 people in high-skilled jobs.

Genentech, the South San Francisco biotech stalwart, is laying off workers for the third time in 15 months as the wider industry sees various cuts.

Eventually, the illusion shattered. Terra Luna’s catastrophic collapse vaporized nearly $60 billion in value, crushing investors who had trusted its promises.

The annual Biotechnology Innovation Organization trade show is expected to bring about 20,000 participants to Boston starting on Monday. Here are the expected key topics of discussion.

Main Square Development plans massive 1,500-acre, 3,800-home Terra Nova mixed-use community in Terrell, east of Dallas.

Biotech Stocks Cash in on the biotech boom with three promising European picks Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns.

Bay Area biotech company Synthego, after raising $392 million, forced into bankruptcy Synthego, which develops gene editing tools for researchers, has a plan in place to sell to a hedge fund ...